Low IDL causes: Difference between revisions
Jump to navigation
Jump to search
Ochuko Ajari (talk | contribs) |
Ochuko Ajari (talk | contribs) |
||
| Line 127: | Line 127: | ||
===Causes in Alphabetical Order=== | ===Causes in Alphabetical Order=== | ||
*Estrogen plus simvastatin combination therapy<ref name="pmid10781640">{{cite journal| author=Wakatsuki A, Okatani Y, Ikenoue N| title=Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia. | journal=Atherosclerosis | year= 2000 | volume= 150 | issue= 1 | pages= 103-11 | pmid=10781640 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10781640 }} </ref> | |||
*Extended-release niacin/laropiprant and simvastatin<ref name="pmid22658147">{{cite journal| author=Ballantyne C, Gleim G, Liu N, Sisk CM, Johnson-Levonas AO, Mitchel Y| title=Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia. | journal=J Clin Lipidol | year= 2012 | volume= 6 | issue= 3 | pages= 235-43 | pmid=22658147 | doi=10.1016/j.jacl.2011.11.004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22658147 }} </ref> | |||
*Familial apolipoprotein AI and apolipoprotein CIII deficiency<ref name="pmid6501564">{{cite journal| author=Forte TM, Nichols AV, Krauss RM, Norum RA| title=Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis. | journal=J Clin Invest | year= 1984 | volume= 74 | issue= 5 | pages= 1601-13 | pmid=6501564 | doi=10.1172/JCI111576 | pmc=PMC425337 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6501564 }} </ref> | |||
*[[Lipoprotein lipase deficiency]] | |||
*[[Lovastatin]]<ref name="pmid8963728">{{cite journal| author=Mack WJ, Krauss RM, Hodis HN| title=Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. | journal=Arterioscler Thromb Vasc Biol | year= 1996 | volume= 16 | issue= 5 | pages= 697-704 | pmid=8963728 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8963728 }} </ref> | |||
*[[Pravastatin]]<ref name="pmid10412757">{{cite journal| author=Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H| title=Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. | journal=Kidney Int Suppl | year= 1999 | volume= 71 | issue= | pages= S134-6 | pmid=10412757 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10412757 }} </ref><ref name="pmid12860210">{{cite journal| author=Lee SJ, Sacks FM| title=Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus. | journal=Am J Cardiol | year= 2003 | volume= 92 | issue= 2 | pages= 121-4 | pmid=12860210 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12860210 }} </ref> | |||
*[[Statins]] | |||
==References== | ==References== | ||
Revision as of 19:28, 5 November 2013
|
Intermediate Density Lipoprotein Microchapters |
|
Clinical Correlation |
|---|
|
Treatment |
|
Case Studies |
|
Low IDL causes On the Web |
|
American Roentgen Ray Society Images of Low IDL causes |
|
Directions to Hospitals Treating Intermediate density lipoprotein |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Causes
Life Threatening Causes
Common Causes
Causes by Organ System
| Cardiovascular | No underlying causes |
| Chemical/Poisoning | No underlying causes |
| Dental | No underlying causes |
| Dermatologic | No underlying causes |
| Drug Side Effect | No underlying causes |
| Ear Nose Throat | No underlying causes |
| Endocrine | No underlying causes |
| Environmental | No underlying causes |
| Gastroenterologic | No underlying causes |
| Genetic | No underlying causes |
| Hematologic | No underlying causes |
| Iatrogenic | No underlying causes |
| Infectious Disease | No underlying causes |
| Musculoskeletal/Orthopedic | No underlying causes |
| Neurologic | No underlying causes |
| Nutritional/Metabolic | No underlying causes |
| Obstetric/Gynecologic | No underlying causes |
| Oncologic | No underlying causes |
| Ophthalmologic | No underlying causes |
| Overdose/Toxicity | No underlying causes |
| Psychiatric | No underlying causes |
| Pulmonary | No underlying causes |
| Renal/Electrolyte | No underlying causes |
| Rheumatology/Immunology/Allergy | No underlying causes |
| Sexual | No underlying causes |
| Trauma | No underlying causes |
| Urologic | No underlying causes |
| Miscellaneous | No underlying causes |
Causes in Alphabetical Order
- Estrogen plus simvastatin combination therapy[1]
- Extended-release niacin/laropiprant and simvastatin[2]
- Familial apolipoprotein AI and apolipoprotein CIII deficiency[3]
- Lipoprotein lipase deficiency
- Lovastatin[4]
- Pravastatin[5][6]
- Statins
References
- ↑ Wakatsuki A, Okatani Y, Ikenoue N (2000). "Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia". Atherosclerosis. 150 (1): 103–11. PMID 10781640.
- ↑ Ballantyne C, Gleim G, Liu N, Sisk CM, Johnson-Levonas AO, Mitchel Y (2012). "Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia". J Clin Lipidol. 6 (3): 235–43. doi:10.1016/j.jacl.2011.11.004. PMID 22658147.
- ↑ Forte TM, Nichols AV, Krauss RM, Norum RA (1984). "Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis". J Clin Invest. 74 (5): 1601–13. doi:10.1172/JCI111576. PMC 425337. PMID 6501564.
- ↑ Mack WJ, Krauss RM, Hodis HN (1996). "Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression". Arterioscler Thromb Vasc Biol. 16 (5): 697–704. PMID 8963728.
- ↑ Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H (1999). "Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients". Kidney Int Suppl. 71: S134–6. PMID 10412757.
- ↑ Lee SJ, Sacks FM (2003). "Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus". Am J Cardiol. 92 (2): 121–4. PMID 12860210.